Bonesupport Holding (OM:BONEX) Posted Stronger Earnings, Is The 13% Discount Still There?

Bonesupport Holding (OM:BONEX) just paired a completed share buyback of 641,320 shares for SEK 142.6 million with third quarter and nine month results that showed higher sales, earnings and earnings per share versus a year earlier.

The recent buyback and earnings release sit alongside a sharp shift in sentiment around Bonesupport Holding, with a 30 day share price return of 46.00% and an 82.58% year to date share price gain. The 5 year total shareholder return of about 7x points to a longer running re rating story that investors are reassessing as new financial data comes through.

Capitalize on the momentum around Bonesupport Holding by scanning a curated 614 high quality undiscovered gems with improving financials and the potential to be re-rated as new results land.

After that surge in Bonesupport Holding on strong reported earnings and a completed buyback, the debate shifts. Does the current price still leave enough upside in the risk reward for new buyers?

Most Popular Narrative: 13% Undervalued

Bonesupport Holding closed at SEK325, against a widely followed fair value estimate of SEK374.67 that reflects detailed cash flow and margin assumptions. The discussion now turns to what needs to go right for that gap to close.

The launch momentum for CERAMENT G in the U.S. is accelerating, with a continued trend of high repeat usage and expansion into additional indications among existing customers, which is expected to positively impact future revenue growth and overall earnings power.

The shift in orthopedic infection treatment toward combining local antibiotics with shorter systemic courses, supported by the SOLARIO trial results, is starting to align surgeon behavior and hospital protocols with CERAMENT G’s profile, which can support higher procedure volumes and revenue growth for Bonesupport Holding.

See why 32 investors see Bonesupport Holding as 13% undervalued.

Result: Fair Value of SEK374.67 (UNDERVALUED)

Still, the story around Bonesupport Holding can change quickly if U.S. hospital purchasing pauses persist or if lingering questions on CERAMENT G elution slow surgeon adoption.

Find out about the key risks to this Bonesupport Holding narrative.

Another View: Bonesupport Holding Looks Expensive On Earnings

On the flip side of the fair value work, Bonesupport Holding trades on a P/E of 78x, versus a fair ratio of 52.7x, Swedish peers at 31.4x and the broader European biotech group at 16.8x. That kind of premium raises a simple question. How much execution risk are you prepared to pay for?

For readers who prefer anchoring on earnings based checks rather than cash flow models, See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Sentiment around Bonesupport Holding is split, which is exactly why the numbers deserve a closer look so you can move quickly and shape your own view. To see both sides in one place, review the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Bonesupport Holding?

If the Bonesupport Holding story has sharpened your thinking, do not stop here. Broaden your watchlist and give yourself more quality options.

• Target future upside on your terms by scanning a curated 204 high quality undervalued stocks that filters for quality businesses priced below what their fundamentals might justify.
• Seek staying power in tougher markets by reviewing a 218 resilient stocks with low risk scores that focuses on resilient companies with sturdier profiles.
• Prioritize financial strength by tracking a list of solid balance sheet and fundamentals (199 results) that surfaces firms with cleaner debt positions and healthier fundamentals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com